Antipsychotic-induced increase in lipid biosynthesis: Activation through inhibition?

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 307-309

  Skrede, Silje ^a,b   Steen, Vidar Martin ^a,b   Fernø, Johan ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RISPERIDONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; ZIPRASIDONE;

CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; DRUG TARGETING; FEEDBACK SYSTEM; HUMAN; LIPOGENESIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSCRIPTION INITIATION;

ANTIPSYCHOTIC AGENTS; CHOLESTEROL; FATTY ACIDS; HUMANS;

EID: 84872432545     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E034736     Document Type: Note

References (25)

1. Meyer, J. M., and C. E. Koro. 2004. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70: 1-17. (Pubitemid 38916622)
2. Newcomer, J. W., J. M. Meyer, R. A. Baker, J. M. Eudicone, A. Pikalov, E. Vester-Blokland, R. D. McQuade, D. T. Crandall, W. H. Carson, and R. N. Marcus, et al. 2008. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr. Res. 106: 300-307.
3. Newcomer, J. W., and C. H. Hennekens. 2007. Severe mental illness and risk of cardiovascular disease. JAMA. 298: 1794-1796. (Pubitemid 47598448)
4. Buchanan, R. W., J. Kreyenbuhl, D. L. Kelly, J. M. Noel, D. L. Boggs, B. A. Fischer, S. Himelhoch, B. Fang, E. Peterson, and P. R. Aquino, et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 36: 71-93.
5. Reynolds, G. P., and S. L. Kirk. 2010. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 125: 169-179.
6. Summerly, R., and H. Yardley. 1965. The effect of a substituted fluorobutyrophenone (haloperidol) on the metabolism of sterols in rat skin. Biochem. J. 96: 30.
7. Adams, C. M., J. L. Goldstein, and M. S. Brown. 2003. Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc. Natl. Acad. Sci. USA. 100: 10647-10652. (Pubitemid 37140082)
8. Lange, Y., and T. L. Steck. 1994. Cholesterol homeostasis. Modulation by amphiphiles. J. Biol. Chem. 269: 29371-29374. (Pubitemid 24365077)
9. Lange, Y., J. Ye, M. Rigney, and T. L. Steck. 1999. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J. Lipid Res. 40: 2264-2270. (Pubitemid 30017528)
10. Lange, Y., J. Ye, and T. L. Steck. 1998. Circulation of cholesterol between lysosomes and the plasma membrane. J. Biol. Chem. 273: 18915-18922. (Pubitemid 28366279)
11. Yang, L. H., T. M. Chen, S. T. Yu, and Y. H. Chen. 2007. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol. Res. 56: 202-208.
12. Fernø, J., M. B. Raeder, A. O. Vik-Mo, S. Skrede, M. Glambek, K. J. Tronstad, H. Breilid, R. Lovlie, R. K. Berge, and C. Stansberg, et al. 2005. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5: 298-304. (Pubitemid 41486229)
13. Canfrán-Duque, A., M. Casado, Ó. Pastor, J. Sánchez-Wandelmer, G. Peña, M. Lerma, P. Mariscal, P. Bracher, M. Lasunción, and R. Busto. 2013. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J. Lipid Res. 54: 310-324.
14. Sánchez-Wandelmer, J., A. M. Hernandez-Pinto, S. Cano, A. Davalos, G. de la Pena, L. Puebla-Jimenez, E. Arilla-Ferreiro, M. A. Lasuncion, and R. Busto. 2009. Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. J. Neurochem. 110: 631-640.
15. Sánchez-Wandelmer, J., A. Davalos, G. de la Pena, S. Cano, M. Giera, A. Canfran-Duque, F. Bracher, A. Martin-Hidalgo, C. Fernandez-Hernando, and M. A. Lasuncion, et al. 2010. Haloperidol disrupts lipid rafts and impairs insulin signaling in SH-SY5Y cells. Neuroscience. 167: 143-153.
16. Kristiana, I., L. J. Sharpe, V. S. Catts, L. H. Lutze-Mann, and A. J. Brown. 2010. Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J. 10: 396-407.
17. Fernø, J., S. Skrede, A. O. Vik-Mo, B. Havik, and V. M. Steen. 2006. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 7: 69.
18. Lauressergues, E., B. Staels, K. Valeille, Z. Majd, D. W. Hum, P. Duriez, and D. Cussac. 2010. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch. Pharmacol. 381: 427-439.
19. Fernø, J., A. O. Vik-Mo, G. Jassim, B. Havik, K. Berge, S. Skrede, O. A. Gudbrandsen, J. Waage, N. Lunder, and S. Mork, et al. 2009. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl.). 203: 73-84.
20. Jassim, G., S. Skrede, M. J. Vazquez, H. Wergedal, A. O. Vik-Mo, N. Lunder, C. Dieguez, A. Vidal-Puig, R. K. Berge, and M. Lopez, et al. 2012. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl.). 219: 783-794.
21. Minet-Ringuet, J., P. C. Even, P. Valet, C. Carpene, V. Visentin, D. Prevot, D. Daviaud, A. Quignard-Boulange, D. Tome, and R. de Beaurepaire. 2007. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol. Psychiatry. 12: 562-571. (Pubitemid 46816768)
22. Skrede, S., J. Fernø, M. J. Vazquez, S. Fjaer, T. Pavlin, N. Lunder, A. Vidal-Puig, C. Dieguez, R. K. Berge, and M. Lopez, et al. 2012. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int. J. Neuropsychopharmacol. 15: 163-179.
23. Callaghan, J. T., R. F. Bergstrom, L. R. Ptak, and C. M. Beasley.1999. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37: 177-193.
24. Bushe, C. J., C. J. Slooff, P. M. Haddad, and J. L. Karagianis. 2012. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J. Clin. Psychiatry. 73: e749-e755.
25. Rummel-Kluge, C., K. Komossa, S. Schwarz, H. Hunger, F. Schmid, C. A. Lobos, W. Kissling, J. M. Davis, and S. Leucht. 2010. Head-tohead comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 123: 225-233.